Neurosciences Medicine

Neurosciences Medicine

The Neurosciences Medicine (NSM) research program at the DCRI is dedicated to taking bold action to find solutions to challenging neurological conditions like depression, Alzheimer's disease, and epilepsy.

Boldly Answering Today's Neuroscience Challenges

Driven by psychiatry and neurology faculty, the DCRI's Neurosciences Medicine program develops, conducts, and supports innovative Phase I–IV clinical trials addressing neurological and psychiatric conditions for pediatric, adolescent, adult, and geriatric patient populations.

Our experienced and consistent clinical operations teams expertly manage all aspects of neurosciences medicine clinical trials, including:

  • Early-phase PK/PD and POC trials, conducted in our onsite phase I unit
  • Game and device/sham-controlled trial design and conduct
  • Pediatrics (microdosing, PK)
  • Neurocritical care trials
  • Electroencephalography
  • Polysomnography
  • Nerve conduction studies and electromyography
  • Neuroimaging
  • Immune monitoring: mechanistic and predictive biomarkers
  • Translational studies
  • Large multisite trials
  • Full-service CRO activities (protocol design/development, data management, biostatistics, pharmacokinetics, site management/monitoring)
Our Clinical Research Expertise
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Autism Spectrum Disorder
  • Mood and anxiety disorders
  • Epilepsy
  • Sleep disorders
  • Neuromuscular disorders
  • Stroke
  • Neurodegenerative diseases


Collecting Data on Pediatric Migraines

About 5 percent of children are diagnosed with migraine by age 10, and a DCRI-led registry could open the door for drug development in this space.

A New Model to Predict Alzheimer’s Progression

DCRI’s Sheng Luo, PhD and his co-authors have found that the novel combination of baseline information and longitudinal profiles of multiple clinical and neuroimaging markers can more accurately predict a patient's progression to Alzheimer’s disease.

Making Discoveries to Improve Outcomes

Patients who experience a stroke sometimes must transfer hospitals before receiving a life-saving therapy. A DCRI study found this transfer process is associated with an increased risk of negative outcomes.

Studying a Digital Treatment for ADHD

Scott Kollins, PhD, DCRI faculty and co-director of DCRI's Digital Health Solutions group, shares an update on his research in ADHD and discusses the DCRI’s interest in working on trials to provide clinical evidence for digital therapeutics. Kollins and Daniel Laskowitz, MD, MHS, DCRI Neuroscience Medicine director, recently announced the results of a clinical trial that investigated the effectiveness of Akili's AKL-T01, a video-game based treatment for the treatment of ADHD in children. This was the first clinical trial to study the effects of the treatment in both patients receiving a combination of AKL-T01 and ADHD medications and in patients receiving only AKL-T01. Read more about this study:

Neurosciences Medicine Leadership at the DCRI

Daniel Laskowitz, MD, MHS, Director

Daniel Laskowitz graduated from the Duke University School of Medicine. After completing his residency at the Hospital of the University of Pennsylvania, he returned to Duke to complete his residency in cerebrovascular disease and neurocritical care.

Laskowitz's research interests include exploring new therapeutic interventions in the clinical setting of stroke, intracranial hemorrhage, and closed head injury. He is committed to translational research and has several active clinical research protocols designed to bring the research performed in the Multidisciplinary Research Laboratories to the clinical arena.